CPT code 80157 identifies a lab test that measures the free (unbound) concentration of carbamazepine in a patient specimen. This measurement is clinically important because the free fraction represents the active portion of the drug and can guide therapeutic drug monitoring, dose adjustments, and safety assessments for patients treated for epilepsy and other neurologic or psychiatric conditions. Nationally, assays for free anticonvulsant levels inform clinical management and have implications for lab service utilization and payer coverage policies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, typical site of service, and common billing modifiers. The publication highlights what clinicians and billing professionals need to know about where this service is performed, why free-level testing differs from total drug level testing, and how payers commonly approach laboratory toxicology and therapeutic drug monitoring services.

The report provides benchmarks and policy-relevant context where available, summarizes typical use cases in therapeutic drug monitoring, and notes missing input fields when necessary. Data not available in the input will be identified explicitly in relevant sections.